NC-MG-FOODS
MG Foods of Charlotte, NC is recalling various Turkey Sandwiches due to a potential contamination of Listeria monocytogenes . Listeria monocytogenes is an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Although healthy individuals may suffer only short-term symptoms such as high fever, severe headache, stiffness, nausea, abdominal pain and diarrhea, a Listeria monocytogenes infection can cause miscarriages and stillbirths among pregnant women.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210310005930/en/
The products were distributed between March 3, 2021 and March 5, 2021 and packaged in clear plastic wedges & paper bags. The products were sold at distributors located at the Charlotte Douglas Airport and via vending machines and micro markets located in business locations in Georgia, North Carolina, South Carolina, and West Virginia. The company reacted swiftly and as of end-of-day March 5, 2021 affected products were removed from sale at all locations.
No illnesses have been reported to date.
On March 2, 2021 during routine environmental testing the company detected the presence of Listeria on surface areas where the recalled products were produced. Out of an abundance of caution, MG Foods is recalling the products due to the potential that some product may be contaminated with Listeria monocytogenes .
Products recalled at the Charlotte Douglas Airport are:
PRODUCT |
SIZE |
UPC |
CONTAINER |
USE BY DATES |
MG Foods Combo Half & Half |
6.82 oz |
1 00000 50069 9 |
Plastic Wedge |
3/9/2021 |
MG Foods Turkey & Cheddar BLT |
6.9 oz |
1 00000 50068 2 |
Plastic Wedge |
3/7/2021 |
MG Foods Turkey & Swiss Croissant |
7.5 oz |
1 00000 50011 8 |
Brown Bag |
3/7/2021 |
Products recalled in vending machines and micro markets located in Georgia, North Carolina, South Carolina and West Virginia are:
PRODUCT |
SIZE |
UPC |
CONTAINER |
USE BY DATES |
Fresh to You Club on Toast |
10.3 oz |
MGF0930 |
Plastic Wrap |
3/7/2021 |
Fresh to You Club Panini |
8.50 oz |
MGF9844 |
Plastic Wrap |
3/7/2021 |
Fresh to You Club Sub |
9.14 oz |
C0932 |
Plastic Wrap |
3/7/2021 |
Fresh to You Club Sub |
9.14 oz |
MGF9100 |
Plastic Wrap |
3/7/2021 |
Fresh to You Deluxe Triple Decker Club |
12.17 oz |
MGF9719 |
Plastic Wrap |
3/7/2021 |
Fresh to You Ham & Turkey Combo |
5.85 oz |
MGF3054 |
Plastic Wedge |
3/9/2021 |
Fresh to You Ham & Turkey Combo on 12 Grain |
7.20 oz |
MGF6011 |
Plastic Wedge |
3/9/2021 |
Fresh to You Jumbo Turkey & Cheese Sub |
6.74 oz |
MGF1002 |
Plastic Wrap |
3/9/2021 |
Fresh to You Market Club |
11.85 oz |
MGF9800 |
Plastic Wrap |
3/7/2021 |
Fresh to You Market Ham & Turkey Combo |
5.85 oz |
MGF23054 |
Plastic Wrap |
3/9/2021 |
Fresh to You Market Shaved Turkey & Cheese |
4.55 oz |
MGF25571 |
Plastic Wedge |
3/9/2021 |
Fresh to You Shaved Turkey & Cheese |
4.55 oz |
MGF5571 |
Plastic Wedge |
3/9/2021 |
Fresh to You Turkey & Baby Swiss on a Honey Brown Roll |
9.42 oz |
MGF9703 |
Plastic Wrap |
3/7/2021 |
Fresh to You Turkey & Cheddar Club |
10.02 oz |
MGF9710 |
Plastic Wedge |
3/7/2021 |
Fresh to You Turkey & Cheese Cut |
6.56 oz |
MGF0596 |
Plastic Wedge |
3/9/2021 |
Fresh to You Turkey & Cheese Hoagie |
6.35 oz |
MGF0597 |
Plastic Wrap |
3/9/2021 |
Fresh to You Turkey & Sun-Dried Tomato Aioli on Pita |
8.29 oz |
MGF9806 |
Plastic Wrap |
3/7/2021 |
Fresh to You Turkey & Swiss on a Kaiser Roll |
8.1 oz |
MGF9712 |
Plastic Wrap |
3/7/2021 |
Fresh to You Turkey & Swiss on a Wheat Roll |
5.22 oz |
MGF0854 |
Plastic Wrap |
3/9/2021 |
Fresh to You Turkey & Swiss on Whole Wheat |
3.9 oz |
MGF0283 |
Plastic Wedge |
3/9/2021 |
Fresh to You Turkey Club Croissant |
7.94 oz |
MGF9103 |
Plastic Square |
3/7/2021 |
Fresh to You Turkey Cranberry Pita |
9.0 oz |
MGF9804 |
Plastic Wrap |
3/7/2021 |
Fresh to You Turkey Melt Croissant |
6.7 oz |
MGF3032 |
Plastic Wrap |
3/9/2021 |
Fresh to You Tuscan Turkey Ciabatta |
9.18 oz |
MGF9810 |
Plastic Wrap |
3/7/2021 |
MG Foods Combo Half & Half |
6.82 oz |
1 00000 50069 9 |
Plastic Wedge |
3/9/2021 |
MG Foods The Club Sub |
8.5 oz |
1 00000 50002 6 |
Brown Bag |
3/9/2021 |
MG Foods Turkey & Cheddar BLT |
6.9 oz |
1 00000 50068 2 |
Plastic Wedge |
3/7/2021 |
MG Foods Turkey & Pepperjack Sub |
7.9 oz |
1 00000 50055 2 |
Brown Bag |
3/7/2021 |
MG Foods Turkey & Provolone BLT |
8.1 oz |
1 00000 50065 1 |
Plastic Wedge |
3/7/2021 |
MG Foods Turkey & Provolone on 12 Grain |
8.9 oz |
1 00000 50066 8 |
Plastic Wedge |
3/7/2021 |
MG Foods Turkey & Swiss Croissant |
7.5 oz |
1 00000 50011 8 |
Brown Bag |
3/7/2021 |
Product labels are attached for identification of products.
Consumers who have purchased these products are urged to discard any remaining product. Consumers may contact MG Foods at 1-855-424-8390 Monday thru Friday 7:00 am – 7:00 pm ET for any questions related to this recall or to request a full refund.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005930/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom